CareFusion to Resume Shipping Alaris(R) Infusion Products

SAN DIEGO, July 10 /PRNewswire/ -- CareFusion Corporation, the company that
will become public from the planned spinoff of Cardinal Health's clinical and
medical products businesses, today announced it will immediately resume
customer implementations of its Alaris(R) PC units and PCA (Patient Controlled
Analgesia) modules following a shipping hold announced in March.

The company is ready to resume shipments following 510(k) clearance from the
Food and Drug Administration (FDA) for a software correction that will be
implemented on new Alaris PC units.

"The 510(k) clearance for our software correction is another important
milestone in our continued progress under the amended consent decree," said
Dwight Winstead, chief operating officer of CareFusion. "We will continue to
work closely with the FDA to fulfill all of our obligations under the amended
consent decree and execute within our new quality system to manufacture
products that are among the safest in the industry."

The 510(k) clearance follows FDA acceptance of the company's corrective action
plan for field remediation of its infusion pumps that was announced on June 9.
For Alaris PC units already with customers, CareFusion will begin implementing
the software correction as part of this corrective action plan.

About CareFusion Corporation
CareFusion Corporation, a wholly owned subsidiary of Cardinal Health (NYSE:
CAH), is expected to become a public company from the planned spinoff of
Cardinal Health's clinical and medical products businesses. The global company
serves the health care industry with products and services that help hospitals
measurably improve the safety and quality of health care. CareFusion develops
market-leading technologies including Alaris(R) IV pumps, Pyxis(R) automated
dispensing and patient identification systems, AVEA and Pulmonetic Systems
ventilation and respiratory products, ChloraPrep(R) and MedMined(TM) services
for infection prevention, neurological monitoring and diagnostic products, V.
Mueller(R) surgical instruments, and an extensive line of products that
support interventional medicine.

CareFusion employs more than 15,000 people across its global operations and
serves customers in 120 countries. The company has applied to have its shares
of common stock listed on the New York Stock Exchange under the ticker symbol
"CFN." More information may be found at www.carefusion.com.

Cautions Concerning Forward-Looking Statements
This news release contains forward-looking statements addressing the planned
spinoff of Cardinal Health's clinical and medical products businesses as a
separate company named CareFusion Corporation, which is dependent upon future
events or developments. These matters are subject to risks and uncertainties
that could cause actual events (including the planned spinoff) and results to
differ materially from those projected, anticipated or implied. These risks
and uncertainties include uncertainties regarding the planned spinoff of
CareFusion, including the timing and terms of any such spinoff and whether
such spinoff will be completed as it is subject to a number of conditions. In
addition, Cardinal Health and CareFusion are subject to additional risks and
uncertainties described in CareFusion's Form 10, as amended, and Cardinal
Health's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments
to those reports) and exhibits to those reports. Except to the extent required
by applicable law, Cardinal Health and CareFusion undertake no obligation to
update or revise any forward-looking statement.

SOURCE CareFusion Corporation

Media, Jim Mazzola, +1-858-617-1203, jim.mazzola@carefusion.com, or Investors,
Carol Cox, +1-858-617-2020, carol.cox@carefusion.com, both of CareFusion
Corporation